Citations

Showing 10 of 108094 citations.

The Suprachoroidal Delivery Route and Exploring the Potential of Cell-Based Therapies for Age-Related Macular Degeneration
Olsen, Timothy W.

Mayo Clinic

Investigative Opthalmology & Visual Science | January 18, 2018 | Volume: 59 | Issue: 1 | Pages: 321

10.1167/iovs.17-23605 | PMID 29346489 Get It

Bacterial gene control by DNA looping using engineered dimeric transcription activator like effector (TALE) proteins
Becker, Nicole A. , Schwab, Tanya L., Clark, Karl J. , Maher, L. James, Clark, Karl J

Mayo Clinic

Nucleic Acids Research | January 18, 2018 | Volume: 46 | Issue: 5 | Pages: 2690-2696

10.1093/nar/gky047 | PMID 29390154 Get It

Parasitic Infections of the Skin and Subcutaneous Tissues
Norgan, Andrew P. , Pritt, Bobbi S. , Pritt, Bobbi S , Norgan, Andrew P

Mayo Clinic

Advances in Anatomic Pathology | January 18, 2018 | Volume: 25 | Issue: 2 | Pages: 106-123

10.1097/pap.0000000000000183 | PMID 29351090 Get It

A variety of arthropods, protozoa, and helminths infect the skin and subcutaneous tissues and may be identified by anatomic pathologists in standard cytology and histology preparations. The specific organisms seen vary greatly with the patient’s exposure history, including travel to or residence in endemic countries. Arthropods are the most commonly encountered parasites in the skin and subcutaneous tissues and include Sarcoptes scabei, Demodex species, Tunga penetrans, and myiasis-causing fly larvae. Protozoal parasites such as Leishmania may also be common in some settings. Helminths are less often seen, and include round worms (eg, Dirofilaria spp.), tapeworms (eg, Taenia solium, Spirometra spp.), and flukes (eg, Schistosoma spp.). This review covers the epidemiologic and histopathologic features of common parasitic infections of the skin and subcutaneous tissues.
Incidence and cost analysis of hospital admission and 30‐day readmission among patients with cirrhosis
Chirapongsathorn, Sakkarin , Krittanawong, Chayakrit , Pendegraft, Richard S., Mara, Kristin C. , Visscher, Sue L. , Loftus, Conor G., Shah, Vijay H. , Talwalkar, Jayant A., Kamath, Patrick S. , Borah, Bijan J. , Shah, Vijay H , Mara, Kristin C , Enders, Felicity

Mayo Clinic

Hepatology Communications | January 18, 2018 | Volume: 2 | Issue: 2 | Pages: 188-198

10.1002/hep4.1137 | PMID 29404526 Get It

We examined risks for first hospitalization and the rate, risk factors, costs, and 1‐year outcome of 30‐day readmission among patients admitted for complications of cirrhosis. Data were retrospectively analyzed for adult patients with cirrhosis residing in Minnesota, Iowa, or Wisconsin and admitted from 2010 through 2013 at both campuses of the Mayo Clinic Hospital in Rochester, MN. Readmission was captured at the two hospitals as well as at community hospitals in the tristate area within the Mayo Clinic Health System. The incidence of hospitalization for complications of cirrhosis was 100/100,000 population, with increasing age and male sex being the strongest risks for hospitalization. For the 2,048 hospitalized study patients, the overall 30‐day readmission rate was 32%; 498 (24.3%) patients were readmitted to Mayo Clinic hospitals and 157 (7.7%) to community hospitals, mainly for complications of portal hypertension (52%) and infections (30%). Readmission could not be predicted accurately. There were 146 deaths during readmission and an additional 105 deaths up to 1 year of follow‐up (50.4% total mortality). Annual postindex hospitalization costs for those with a 30‐day readmission were substantially higher ($73,252) than those readmitted beyond 30 days ($62,053) or those not readmitted ($5,719). At 1‐year follow‐up, only 20.4% of patients readmitted within 30 days were at home. In conclusion, patients with cirrhosis have high rates of hospitalization, especially among men over 65 years, and of unscheduled 30‐day readmission. Readmission cannot be accurately predicted. Postindex hospitalization costs are high; nationally, the annual costs are estimated to be more than $4.45 billion. Only 20% of patients readmitted within 30 days are home at 1 year. (Hepatology Communications 2018;2:188–198)
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Swords, Ronan , Maris, Michael B., Zeidner, Joshua F. , Foran, James M. , Cruz, José C. , Tam, Wayne , Vardhanabhuti, Saran , Pawlikowska-Dobler, Iwona , Faessel, Hélène M. , Dash, Ajeeta B. , Sedarati, Farhad , Dezube, Bruce J., Faller, Douglas V. , Swords, Ronan T , Zeidner, Joshua F , Cruz, Jose , Tam, Wayne , Vardhanabhuti, Saran , Pawlikowska-Dobler, Iwona , Dash, Ajeeta B , Sedarati, Farhad , Faller, Douglas V , Savona, Michael R , Coutré, Steven , Erba, Harry Paul , Berdeja, Jesús G. , Savona, Michael R.

Mayo Clinic

Blood | January 18, 2018 | Volume: 131 | Issue: 13 | Pages: 1415-1424

10.1182/blood-2017-09-805895 | PMID 29348128 Get It

Key Points RP2D of PEV 20 mg/m2 in PEV/AZA combo did not alter toxicity profile of AZA; dose-limiting toxicities were transiently elevated AST/ALT. In treatment-naive older AML patients, the intent-to-treat ORR was 50%.
The Prevalence and Significance of Staphylococcus aureus in Patients with Non–Cystic Fibrosis Bronchiectasis
Metersky, Mark L. , Aksamit, Timothy R. , Choate, Radmila , Daley, Charles L. , Daniels, M. Leigh Anne , DiMango, Angela, Eden, Edward , Griffith, David E. , Johnson, Margaret M. , Knowles, Michael R. , O’Donnell, Anne E., Olivier, Kenneth N., Thomashow, Byron, Tino, Gregory , Turino, Gerard, Winthrop, Kevin , Mannino, David M. , Johnson, Margaret , BARKER, ALAN ROBERT , Salathe, Matthias A. , Turino, Gerard M., Choate, Radmila , O'Donnell, Anne E

Mayo Clinic

Annals of the American Thoracic Society | January 18, 2018 | Volume: 15 | Issue: 3 | Pages: 365-370

10.1513/annalsats.201706-426oc | PMID 29345970 Get It

Abstract Rationale Staphylococcus aureus is commonly cultured from the sputum of patients with bronchiectasis; however, little is known about the prevalence of the organism in these patients, the characteristics of patients who have grown the organism, or its implications. Objectives Determine the relationship between S. aureus and pulmonary function, frequency of exacerbations, and frequency of hospitalization in patients with bronchiectasis Methods The Bronchiectasis Research Registry is a database of adults with non–cystic fibrosis bronchiectasis identified from 13 sites within the United States. Baseline and follow-up demographic, spirometric, microbiologic, and therapeutic data were entered into a central web-based database. Patients were grouped into three cohorts based on their previous respiratory cultures at the time of entry into the Registry: 1) no prior S. aureus or glucose-nonfermenting gram-negative bacilli (NF-GNB) (Pseudomonas, Stenotrophomonas, or Burkholderia spp.); 2) prior S. aureus at least once; or 3) no prior S. aureus but prior NF-GNB at least once. The association between S. aureus isolation and pulmonary function and frequency of exacerbations and hospital admissions was assessed, both at baseline and after 1 year of follow-up. Results S. aureus was cultured from 94 of 830 patients (11.3%) included in the analysis. Patients who had grown S. aureus before entry into the Registry had a frequency of prior exacerbations and baseline pulmonary function that was between that of patients who had grown NF-GNB and those who had grown neither NF-GNB or S. aureus. Similarly, at the first follow-up visit after study entry, patients who had grown S. aureus had a frequency of exacerbations and hospitalizations that was between those of patients who had grown NF-GNB and those who had grown neither NF-GNB nor S. aureus. However, in multivariate analysis, S. aureus was not associated with pulmonary function, frequency of exacerbation, or hospital admissions. There were no significant differences in patient characteristics or outcomes between patients who had methicillin-sensitive and methicillin-resistant S. aureus. Conclusions Staphylococcus aureus does not appear to be an independent risk factor for severe disease in patients with bronchiectasis enrolled in the Bronchiectasis Research Registry.
A Blast from the Past—Back to the 1970s
Sultan, Shahnaz , Murad, M. Hassan , Murad, M Hassan , Dahm, Philipp

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 18, 2018 | Volume: 197 | Issue: 11 | Pages: 1500-1501

10.1164/rccm.201711-2186le | PMID 29345971 Get It

Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity
Morris, Marc, Stewart, Samuel A. , Heisler, Courtney , Sandborn, William J. , Loftus, Edward V. , Zello, Gordon A. , Fowler, Sharyle , Jones, Jennifer , Loftus, Edward V

Mayo Clinic

Inflammatory Bowel Diseases | January 18, 2018 | Volume: 24 | Issue: 2 | Pages: 277-285

10.1093/ibd/izx018 | PMID 29361090 Get It

Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, Joshua D. , Li, Lu , Wang, Yuxuan , Thoburn, Christopher J. , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A. , Wong, Fay , Mattox, Austin K. , Hruban, Ralph H. , Wolfgang, Christopher L. , Molin, Marco Dal , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Browne, J. Dale, Tie, Jeanne , Wong, Hui‐Li , Mansfield, Aaron S. , Jen, Jin , Falconi, Massimo , Allen, Peter J. , Zhou, Shibin , Díaz, Luis A. , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Thoburn, Christopher , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A , Wong, Fay , Mattox, Austin , Wolfgang, Christopher L , Roden, Richard , Klein, Alison P , Ptak, Janine , Dobbyn, Lisa , Schaefer, Joy , Silliman, Natalie , Schoen, Robert E , Brand, Randall E , Tie, Jeanne , Wong, Hui-Li , Mansfield, Aaron S , Jen, Jin , Zhou, Shibin , Diaz, Luis A , Tomasetti, Cristian , Kinzler, Kenneth W , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Wang, Yuxuan , Afsari, Bahman , Goggins, Michael , Wang, Tian‐Li , Klein, Alison P. , Popoli, Maria , Vogelstein, Joshua T , Schoen, Robert E. , Brand, Randall E. , Gibbs, Peter , Hanash, Samir , Bettegowda, Chetan , Massimo, Falconi

Mayo Clinic

Science | January 18, 2018 | Volume: 359 | Issue: 6378 | Pages: 926-930

10.1126/science.aar3247 | PMID 29348365 Get It

SEEK and you may find cancer earlier Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid genetic evolution limits its response to drugs, have fueled interest in methodologies for earlier detection of the disease. Cohen et al. developed a noninvasive blood test, called CancerSEEK that can detect eight common human cancer types (see the Perspective by Kalinich and Haber). The test assesses eight circulating protein biomarkers and tumor-specific mutations in circulating DNA. In a study of 1000 patients previously diagnosed with cancer and 850 healthy control individuals, CancerSEEK detected cancer with a sensitivity of 69 to 98% (depending on cancer type) and 99% specificity. Science , this issue p. 926 ; see also p. 866
Salvage of Implant-Based Breast Reconstruction in Nipple-Sparing Mastectomies With Autologous Flaps
Qureshi, Ali A, Oliver, Jeremie D. , Parikh, Rajiv P. , Tenenbaum, Marissa M. , Myckatyn, Terence M. , Oliver, Jeremie D , Qureshi, Ali A

Mayo Clinic

Aesthetic Surgery Journal | January 18, 2018 | Volume: 38 | Issue: 7 | Pages: 734-741

10.1093/asj/sjx247 | PMID 29360922 Get It